Figure 9.

(I) An illustration depicting the use of E-PSiNPs as a vehicle for targeted cancer chemotherapy; (II) At 24 hours after receiving an intravenous injection of DOX, DOX@PSiNPs, or DOX@E-PSiNPs at a dosage of 0.5 mg kg-1, DOX and CD31-labeled tumor vasculature were observed colocalizing in tumor sections of mice containing the H22 tumor; (III) After being intravenously injected with PBS, E PSiNPs, free DOX, DOX@PSiNPs, or DOX@E PSiNPs at a dosage of 0.5 mg/kg, or free DOX at a dosage of 4 mg/kg once every three days for five times, the primary organs of mice having H22 tumors were stained with H&E. Reproduced with the permission from ref. 114. Fig. 1, Fig. 6, and Fig. S.30 (Springer Nature©2019).